Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) posted its earnings results on Monday. The company reported $0.21 earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by ($0.01), Zacks reports. The business had revenue of $329.31 million for the quarter, compared to analysts' expectations of $321.21 million.
Guardian Pharmacy Services Price Performance
GRDN stock traded down $0.30 during mid-day trading on Friday, reaching $24.62. 88,787 shares of the company traded hands, compared to its average volume of 146,109. Guardian Pharmacy Services has a fifty-two week low of $14.16 and a fifty-two week high of $26.91. The firm's 50 day moving average price is $22.74 and its 200 day moving average price is $21.82.
Institutional Investors Weigh In On Guardian Pharmacy Services
A hedge fund recently bought a new stake in Guardian Pharmacy Services stock. Dynamic Technology Lab Private Ltd acquired a new stake in Guardian Pharmacy Services, Inc. (NYSE:GRDN - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The firm acquired 10,975 shares of the company's stock, valued at approximately $233,000.
Analysts Set New Price Targets
Separately, Truist Financial boosted their target price on shares of Guardian Pharmacy Services from $24.00 to $25.00 and gave the stock a "buy" rating in a research note on Friday, April 11th.
Check Out Our Latest Stock Report on GRDN
About Guardian Pharmacy Services
(
Get Free Report)
Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.
Featured Articles
Before you consider Guardian Pharmacy Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardian Pharmacy Services wasn't on the list.
While Guardian Pharmacy Services currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
